An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

Table 2 Adverse events occurring more than once or in more than one patient

System organ class Preferred term	Mild (%)	Moderate (%)	Total (%)
Gastrointestinal disorders
Diarrhea	2 (22)^a		2 (22)^a
Infections and infestations
Nasopharyngitis	2 (22)		2 (22)
Musculoskeletal and connective tissue disorders
Arthralgia	3 (33)^b		3 (33)^b
Arthritis		2 (22)	2 (22)
Myalgia	1 (11)^a	1 (11)^a	2 (22)^a
Nervous system disorders
Headache	3 (33)^b		3 (33)^b

ISSN: 1478-6362